|Principal Investigator||Kerry Ressler, MD, PhD|
Kerry Ressler, MD, PhD or call 404-727-7739
|Types of Samples||Salivary DNA / GWAS sampling on 5000 subjects, and Whole Blood, Plasma, Serum and Urine on 800 of those subjects.|
|Associated Phenotypic / Genotypic Data||Psychological (self-report and clinical interview) data on 5000 subjects: demographic, geocoding, stress, trauma, depression, PTSD, and other risk as well as resilience phenotypes are available. Physiology (HR, galvanic skin response, acoustic startle response, measures of fear and extinction) on 500 subjects. Neuroimaging data (fMRI resting state, task dependent, and structural) on >100 subjects.|
|Interest in Collaboration||Potentially, depending on the circumstances and questions.|
|More Information||The Sample represents a cross-sectional, epidemiological sampling of subjects (18-65yo; 60% females; 90% African-American) from inner-city Atlanta attending Grady Memorial Hospital outpatient clinics. Although the focus of the study is civilian Posttraumatic Stress Disorder (PTSD), demographic, geocoding, stress, trauma, depression, PTSD, and other risk as well as resilience phenotypes are available.
Up to 40% of the variance determining who develops Posttraumatic Stress Disorder following a severe trauma is genetically heritable. By focusing on genes that differentially associate with presence or absence of PTSD in a similarly highly- traumatized population, we plan to prioritize genes with a high likelihood of critical involvement in the etiology of PTSD. Identifying the genetic pathways involved with PTSD, combined with our increasing understanding of the neural circuitry of fear and stress-dysregulation, will lead to an improved neurobiological understanding, enhanced prevention, and improved treatment of this debilitating and prevalent syndrome.